Skip to main content
. 2015 Nov 16;7(1):473–489. doi: 10.18632/oncotarget.6337

Figure 4. Overexpression of ErbB3 sensitized Hep3B cells to lapatinib.

Figure 4

A. Hep3B cells were transiently transfected with pDsRed vector or pDsred-conjugated ErbB3 for 24 hours followed by 1 μM lapatinib treatment for 5 days. The red fluorescence was detected by fluorescence microscope. B. Hep3B cells were transiently transfected with vector control or ErbB3 followed by lapatinib treatment. The cell viability was determined by crystal violet staining. The protein expression of ErbB3 and internal control-Tubulin were detected by Western blot. C. Hep3B and Hep3Bx were infected with shErbB3 for 5 days. The cell viability was determined by MTT assay. D. Hep3Bx cells were transfected with control or ErbB3 siRNA for 5 days followed by lapatinib treatment. The cell survival was detected by crystal violet staining. The protein expression of ErbB3 and internal control-Tubulin were determined by Western blot. E. Hep3Bx cells were infected with luc shRNA and ErbB3 shRNA for 5 days followed by treatment with lapatinib for 24 hours. The protein expression was detected by Western blot. F. Hep3Bx cells were transfected with control or ErbB3 siRNA followed by lapatinib treatment for 5 days. The sub-G1 population was determined by PI staining in flow cytometry analysis. Statistical analysis was performed by Student's t test. *, p < 0.05; **, p < 0.01; ***, p < 0.001 as compared to control group.